CN113025633B - 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 - Google Patents

编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 Download PDF

Info

Publication number
CN113025633B
CN113025633B CN201911250082.4A CN201911250082A CN113025633B CN 113025633 B CN113025633 B CN 113025633B CN 201911250082 A CN201911250082 A CN 201911250082A CN 113025633 B CN113025633 B CN 113025633B
Authority
CN
China
Prior art keywords
nucleic acid
protein
sequence
cells
nadh dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911250082.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113025633A (zh
Inventor
李斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Niufusi Biological Technology Co ltd
Original Assignee
Wuhan Niufusi Biological Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201911250082.4A priority Critical patent/CN113025633B/zh
Application filed by Wuhan Niufusi Biological Technology Co ltd filed Critical Wuhan Niufusi Biological Technology Co ltd
Priority to KR1020227021339A priority patent/KR20220112262A/ko
Priority to EP20898208.2A priority patent/EP4073244A4/en
Priority to AU2020399898A priority patent/AU2020399898A1/en
Priority to CN202080083006.3A priority patent/CN114929872A/zh
Priority to CA3160809A priority patent/CA3160809A1/en
Priority to PCT/CN2020/134859 priority patent/WO2021115317A1/en
Priority to MX2022006949A priority patent/MX2022006949A/es
Priority to BR112022010321A priority patent/BR112022010321A2/pt
Priority to JP2022534671A priority patent/JP2023505522A/ja
Publication of CN113025633A publication Critical patent/CN113025633A/zh
Priority to US17/361,884 priority patent/US11357869B2/en
Priority to US17/743,813 priority patent/US20220273816A1/en
Application granted granted Critical
Publication of CN113025633B publication Critical patent/CN113025633B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0053—Oxidoreductases (1.) acting on a heme group of donors (1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/99—Oxidoreductases acting on NADH or NADPH (1.6) with other acceptors (1.6.99)
    • C12Y106/99003—NADH dehydrogenase (1.6.99.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y109/00—Oxidoreductases acting on a heme group of donors (1.9)
    • C12Y109/03—Oxidoreductases acting on a heme group of donors (1.9) with oxygen as acceptor (1.9.3)
    • C12Y109/03001—Cytochrome-c oxidase (1.9.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201911250082.4A 2019-12-09 2019-12-09 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 Active CN113025633B (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201911250082.4A CN113025633B (zh) 2019-12-09 2019-12-09 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
BR112022010321A BR112022010321A2 (pt) 2019-12-09 2020-12-09 Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase
AU2020399898A AU2020399898A1 (en) 2019-12-09 2020-12-09 Compositions and methods for treating Leber's hereditary optic neuropathy with NADH dehydrogenase proteins
CN202080083006.3A CN114929872A (zh) 2019-12-09 2020-12-09 用nadh脱氢酶蛋白治疗莱伯遗传性视神经病变的组合物和方法
CA3160809A CA3160809A1 (en) 2019-12-09 2020-12-09 Compositions and methods for treating leber's hereditary optic neuropathy with nadh dehydrogenase proteins
PCT/CN2020/134859 WO2021115317A1 (en) 2019-12-09 2020-12-09 Compositions and methods for treating leber's hereditary optic neuropathy with nadh dehydrogenase proteins
KR1020227021339A KR20220112262A (ko) 2019-12-09 2020-12-09 Nadh 탈수소효소 단백질을 이용한 레버 유전성 시신경병증 치료용 조성물 및 방법
EP20898208.2A EP4073244A4 (en) 2019-12-09 2020-12-09 COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY WITH NADH DEHYDROGENASE PROTEINS
JP2022534671A JP2023505522A (ja) 2019-12-09 2020-12-09 Ｎａｄｈデヒドロゲナーゼタンパク質でレーベル遺伝性視神経症を治療するための組成物及び方法
MX2022006949A MX2022006949A (es) 2019-12-09 2020-12-09 Composiciones y metodos para tratar la neuropatia optica hereditaria de leber con proteinas nadh deshidrogenasa.
US17/361,884 US11357869B2 (en) 2019-12-09 2021-06-29 Compositions and methods for treating leber's hereditary optic neuropathy with NADH dehydrogenase proteins
US17/743,813 US20220273816A1 (en) 2019-12-09 2022-05-13 Compositions and methods for treating leber's hereditary optic neuropathy with nadh dehydrogenase proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911250082.4A CN113025633B (zh) 2019-12-09 2019-12-09 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用

Publications (2)

Publication Number Publication Date
CN113025633A CN113025633A (zh) 2021-06-25
CN113025633B true CN113025633B (zh) 2024-08-27

Family

ID=76329564

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911250082.4A Active CN113025633B (zh) 2019-12-09 2019-12-09 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN202080083006.3A Pending CN114929872A (zh) 2019-12-09 2020-12-09 用nadh脱氢酶蛋白治疗莱伯遗传性视神经病变的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080083006.3A Pending CN114929872A (zh) 2019-12-09 2020-12-09 用nadh脱氢酶蛋白治疗莱伯遗传性视神经病变的组合物和方法

Country Status (10)

Country Link
US (2) US11357869B2 (https=)
EP (1) EP4073244A4 (https=)
JP (1) JP2023505522A (https=)
KR (1) KR20220112262A (https=)
CN (2) CN113025633B (https=)
AU (1) AU2020399898A1 (https=)
BR (1) BR112022010321A2 (https=)
CA (1) CA3160809A1 (https=)
MX (1) MX2022006949A (https=)
WO (1) WO2021115317A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113528510A (zh) 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
SG11202101032VA (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy
AR126727A1 (es) * 2021-08-06 2023-11-08 Wuhan Neurophth Biotechnology Ltd Company Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4
CN115927401B (zh) * 2021-08-23 2025-05-16 纽福斯(苏州)生物科技有限公司 编码nadh泛醌氧化还原酶4号亚基的核酸及其用途
CN114213549B (zh) * 2021-12-24 2024-01-05 上海生物芯片有限公司 定位于线粒体的融合蛋白、接头及其用途
JP2026501611A (ja) * 2022-12-29 2026-01-16 エッジーン インコーポレイテッド レーベル遺伝性視神経症のミトコンドリア塩基変異矯正システム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450747A (zh) * 2014-09-23 2015-03-25 李斌 用于治疗Leber遗传性视神经病变的重组腺相关病毒-NADH脱氢酶亚单位4基因全长以及药剂
CN109970861A (zh) * 2017-12-27 2019-07-05 武汉纽福斯生物科技有限公司 一种靶向线粒体的nd4融合蛋白及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
AU2668897A (en) 1996-04-19 1997-11-12 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5814451A (en) * 1997-01-17 1998-09-29 Incyte Pharmaceuticals, Inc. Subunits of NADH dehydrogenase
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
CN1270222A (zh) * 2000-03-17 2000-10-18 国家人类基因组南方研究中心 一种新的人辅酶ⅰ亚基异构体蛋白及其编码序列
US20020132978A1 (en) 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
BRPI0511764B8 (pt) 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
EP1877559B1 (en) * 2005-04-18 2010-10-13 Mitomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US20130022979A1 (en) 2005-04-18 2013-01-24 Genesis Genomics Inc. 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER
PT1880008E (pt) 2005-05-03 2015-08-27 Inserm Inst Nat De La Santé Et De La Rech Médicale Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada
AU2007324073A1 (en) 2006-10-23 2008-05-29 John Guy Suppression of mitochondrial oxidative stress
WO2008155397A2 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
WO2010040901A1 (en) * 2008-10-07 2010-04-15 Pierre Rustin Alternative oxidase and uses thereof
CA2962219C (en) 2008-10-22 2020-08-25 Quark Pharmaceuticals, Inc. Methods for treating eye disorders
RU2011137486A (ru) * 2009-03-27 2013-05-10 Митомикс Инк. Аберрантная митохондриальная днк, ассоциированные с ней слитые транскрипты, продукты трансляции и гибрадизационные зонды
WO2011094198A1 (en) 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
CN102517304B (zh) 2011-12-16 2013-08-28 中国农业科学院生物技术研究所 重组葡萄糖氧化酶的优化基因及其表达载体和应用
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US20160289674A1 (en) 2012-04-02 2016-10-06 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
CN102634527B (zh) 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
SG11201702116VA (en) 2014-09-17 2017-04-27 Univ Iowa Res Found Viral rna segments as immunomodulatory agents and vaccine components
AU2016291778B2 (en) 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3548039B1 (en) 2016-12-04 2023-07-19 Alavi Khorassani Moghadam, Marcel Victor Ribavirin for use in the treatment of a mitochondrial disease
US20180207293A1 (en) 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
WO2019033119A1 (en) 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
US20210163898A1 (en) 2018-04-16 2021-06-03 The Children's Hospital Of Philadelphia Mitochondrial rna import for treating mitochondrial disease
CA3103231A1 (en) 2018-06-11 2019-12-19 Serge FITOUSSI Recombinant aav vectors and methods of using the same
WO2020000641A1 (zh) 2018-06-29 2020-01-02 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
WO2020010491A1 (zh) 2018-07-09 2020-01-16 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN110846392A (zh) 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 一种重组腺相关病毒或含其的试剂盒及其应用
CN111068071A (zh) 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
CN111073899B (zh) 2018-10-19 2021-01-01 武汉纽福斯生物科技有限公司 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
SG11202101032VA (en) * 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450747A (zh) * 2014-09-23 2015-03-25 李斌 用于治疗Leber遗传性视神经病变的重组腺相关病毒-NADH脱氢酶亚单位4基因全长以及药剂
CN109970861A (zh) * 2017-12-27 2019-07-05 武汉纽福斯生物科技有限公司 一种靶向线粒体的nd4融合蛋白及其制备方法和应用

Also Published As

Publication number Publication date
AU2020399898A1 (en) 2022-05-19
CA3160809A1 (en) 2021-06-17
JP2023505522A (ja) 2023-02-09
CN114929872A (zh) 2022-08-19
KR20220112262A (ko) 2022-08-10
CN113025633A (zh) 2021-06-25
EP4073244A1 (en) 2022-10-19
EP4073244A4 (en) 2024-03-20
BR112022010321A2 (pt) 2022-08-16
US20210353774A1 (en) 2021-11-18
US20220273816A1 (en) 2022-09-01
US11357869B2 (en) 2022-06-14
MX2022006949A (es) 2022-07-13
WO2021115317A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
CN113025633B (zh) 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
US20230257777A1 (en) Compositions and methods for enhanced gene expression
CN111621502B (zh) 视网膜劈裂蛋白的编码序列、其表达载体构建及其应用
US20200121746A1 (en) Adeno-associated virus virions with variant capsids and methods of use thereof
JP7285022B2 (ja) 組換えヒトＩＩ型ミトコンドリアダイニン様ＧＴＰａｓｅの遺伝子配列及びその使用
US11970519B2 (en) Gene therapy vector for treating retinitis pigmentosa disease
US20240067989A1 (en) Compositions and Methods for Treating Retinal Disorders
JP2022505816A (ja) 小型化ジストロフィンおよびそれらの使用
JP2023539368A (ja) コドン最適化したｒｐｇｒｏｒｆ１５遺伝子およびその使用
WO2025247393A1 (zh) 用于治疗Prom1相关视网膜疾病的新型治疗药物
CN110699367B (zh) 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN121569038A (zh) 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法
WO2020077756A1 (zh) Nd4蛋白的编码序列及其应用
WO2020010491A1 (zh) 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN111926021B (zh) 重组人norrin胱氨酸结生长因子表达载体及其应用
WO2020000641A1 (zh) 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
CN111518813B (zh) 视紫红质的编码序列、其表达载体构建及其应用
WO2024083013A1 (zh) 人线粒体动力蛋白样gtp酶及应用
CN111909935B (zh) 重组人卷曲蛋白受体4(fzd4)的表达载体及其应用
CN115279906A (zh) 一种人核因子e2相关因子2的表达载体及其应用
US20260022402A1 (en) Recombinant adeno-associated viral vector for gene delivery
HK40056038A (en) Recombinant human type ii mitochondrial dynein-like gtpase gene sequence and application thereof
WO2026090552A1 (en) Methods of treating amyloid pathology
CN121772934A (zh) 融合多肽、包含其编码基因的表达盒、基因递送载体、药物组合物及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant